This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.1 (other gangliosidosis) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | Mucolipidosis type IV, ML-IV, MCOLN1 deficiency, Mucolipin-1 deficiency, Lysosomal Ca²⁺ channel deficiency, Berman disease (early name) |
| C. Adult onset | Likelihood of first onset in adulthood: low — Mostly diagnosed through psychomotor developmental delay beginning between birth and infancy, but cases in which diagnosis is delayed until adulthood in mild variants have rarely been reported. Corneal clouding may first be noticed in adulthood. |
| 1. History | 1974: Berman et al. described children with corneal clouding and mental retardation → 1977: classified as mucolipidosis type IV → 2000: MCOLN1 gene identified → mucolipin-1 confirmed to be a lysosomal calcium channel. |
| 2. Causes | MCOLN1 gene variants → loss of mucolipin-1 (TRPML1) function → defect in lysosomal calcium release channel → impaired lysosome-endosome fusion and lysosomal exocytosis → accumulation of phospholipids, gangliosides, and mucopolysaccharides. |
| 3. Genetics | MCOLN1 gene (19p13.2), autosomal recessive. In Ashkenazi Jews, two founder variants (IVS3-2A→G, del6.4kb) account for over 95% of cases. Carrier rate in this population about 1/100. |
| 4. General epidemiology | Estimated 300 or fewer affected patients worldwide (ultra-rare). About 1 per 40,000 births in Ashkenazi Jews. Very rarely reported in non-Jewish populations. Very few reports in Korea. |
| 5. Pathophysiology | TRPML1 deficiency → impaired lysosomal calcium release → blocked lysosome-endosome fusion and lysosomal exocytosis → intralysosomal accumulation of phospholipids and gangliosides → blocked autophagic flux → damage to neurons, cornea, and retina. |
| 6. Symptoms | Corneal clouding (several months to 1 year after birth), psychomotor developmental delay (moderate to severe), visual impairment, degenerative retinopathy, hypotonia → spastic quadriplegia. No visceromegaly. Elevated serum gastrin is characteristic. |
| 7. Signs | Slit-lamp examination: corneal stromal clouding. Fundus: retinal pigmentary degeneration, optic pallor. Brain MRI: hypoplastic corpus callosum, white matter abnormalities, T2 hyperintensity of the basal ganglia. Skin biopsy: lysosomal vacuoles. Elevated serum gastrin. |
| 8. Screening | Ashkenazi Jewish population: DNA screening for the two MCOLN1 founder variants. No general population screening. Serum gastrin measurement is a useful screening tool when clinically suspected. |
| 9. Diagnosis | Confirmation: biallelic pathogenic variants of the MCOLN1 gene. Supportive: elevated serum gastrin (almost all patients), lysosomal vacuoles on electron microscopy of skin biopsy, conjunctival biopsy. Urinary enzymes normal (distinguishing it from other MLS). |
| 10. Treatment | No curative treatment (as of 2026). Corneal transplantation, visual aids, rehabilitation. Small-molecule drugs restoring TRPML1 function and gene therapy in preclinical studies. Preclinical efficacy of an mTORC1 inhibitor (rapamycin) reported. |
| 11. Prognosis | Developmental delay is permanent, but the rate of neurodegeneration is slow. Most survive into adulthood. Visual impairment gradually worsens. Functional disability persists due to the absence of curative treatment. |
| 12. Prevention | Ashkenazi Jewish carrier screening, genetic counseling, prenatal diagnosis (MCOLN1 gene analysis), PGT-M. |
| 13. References | Berman et al. 1974 and 9 other references |
Mucolipidosis type IV (ML-IV) began to be known in 1974 when the American ophthalmologist Edward Berman and colleagues first clinically described Jewish infant patients with corneal clouding and mental retardation. In the early period it was sometimes called "Berman syndrome". In 1977 the disease was officially classified as the fourth type of mucolipidosis (Mucolipidosis type IV), but unlike ML-I, II, and III, there is no urinary excretion of oligosaccharides or mucopolysaccharides and serum and leukocyte lysosomal enzyme activities are normal; because of these unique biochemical features, the exact molecular mechanism was difficult to determine for a long time.
In 2000, several independent research teams simultaneously identified the MCOLN1 gene. Bassi et al. and Sun et al. discovered the MCOLN1 gene located on chromosome 19 (19p13.2) in ML-IV patient cohorts and confirmed that its gene product, "mucolipin-1 (TRPML1)", is a calcium-permeable nonselective cation channel of the lysosomal membrane. TRPML1 was the first identified member of the ML (mucolipin) subfamily of the Transient Receptor Potential (TRP) ion channel superfamily. With this discovery, ML-IV was redefined not as a classic lysosomal hydrolase deficiency but as a lysosomal trafficking defect caused by a deficiency of a lysosomal ion channel (membrane protein), pioneering a new molecular category of lysosomal diseases.
Since the 2000s, research on MCOLN1 gene function, identification of the Ashkenazi Jewish founder variants, establishment of MCOLN1-deficient mouse models, and cellular studies of TRPML1 function have been active. During this period it also became known that elevated serum gastrin is observed in almost all ML-IV patients, and it began to be used as a rapid biochemical screening marker. Recently, research on the reciprocal regulation of the mTORC1 signaling pathway and TRPML1 and their relationship with autophagic flux has been active, and preclinical studies of TRPML1 agonists and gene therapy as therapeutic targets are under way.
Mucolipidosis type IV is a lysosomal trafficking disorder caused by pathogenic variants in both alleles of the MCOLN1 gene, resulting in loss of function of the mucolipin-1 (TRPML1) protein. TRPML1 is a calcium-permeable nonselective cation channel located in the lysosomal membrane that releases Ca²⁺ from the lysosomal lumen toward the cytoplasm. This Ca²⁺ release acts as a key signal regulating membrane fusion between lysosomes and late endosomes, lysosomal exocytosis, and lysosome biogenesis.
When TRPML1 function is lost, lysosomal Ca²⁺ release is blocked, reducing the efficiency of lysosome-endosome membrane fusion and blocking lysosomal exocytosis, which expels lysosomal contents outside the cell. As a result, various substances—phospholipids, gangliosides, mucopolysaccharides, proteins, etc.—accumulate secondarily within lysosomes. This means that TRPML1 itself is not an enzyme that directly degrades these substances, emphasizing that this is secondary accumulation due to blocked trafficking. In addition, because autophagosome-lysosome fusion also depends on TRPML1, autophagic flux is blocked in TRPML1 deficiency and damaged organelles are not cleared.
The spectrum of MCOLN1 gene variants is relatively limited. In Ashkenazi Jews, over about 95% of all patients have one of two founder variants, or both in compound heterozygous form: (1) IVS3-2A→G (a splice acceptor site variant of intron 3) and (2) del6.4kb (a large deletion of about 6.4 kb including exons 1–6 of the MCOLN1 gene). In non-Jewish patients, various missense, nonsense, and frameshift variants have been reported. Clinical severity correlates with residual TRPML1 function: complete loss of function produces the typical severe phenotype, whereas variants with some residual function produce a mild phenotype.
The MCOLN1 gene is located on the short arm of chromosome 19 (19p13.2) and consists of 13 exons encoding a 5.5 kb mRNA. The translated mucolipin-1 protein is 580 amino acids long and adopts a TRP channel structure with six transmembrane domains (TM1–TM6). The pore loop between TM5 and TM6 determines Ca²⁺ permeability, and the N- and C-termini face the cytoplasm. TRPML1 functions by forming multimers (most commonly tetramers) in the lysosomal membrane.
The mode of inheritance is autosomal recessive. In the Ashkenazi Jewish population, the carrier frequency of each of the two founder variants (IVS3-2A→G, del6.4kb) is about 1/100, and considering the combined carrier rate of the two variants, the frequency of affected individuals in this population is about 1/40,000. Both variants are severe loss-of-function variants (null alleles), so the typical severe phenotype is expressed even in compound heterozygous patients.
Variants reported in non-Jewish patients include p.Phe408del (phenylalanine deletion), p.Leu106Pro, and various splicing variants. Mild phenotypes have been reported with some missense variants, and partial preservation of channel function is associated with a mild clinical picture. Besides MCOLN1, TRPML2 (MCOLN2, 1p22) and TRPML3 (MCOLN3, 1p22) belong to the same subfamily, but their deficiency does not cause the ML-IV phenotype.
In the Ashkenazi Jewish population, carrier testing is performed by DNA testing for the two founder variants before a planned pregnancy, and if negative for these variants the residual risk is very low. In non-Jewish individuals, carrier testing is possible based on a variant identified in the family; if the familial variant is not identified, full sequencing of the MCOLN1 gene is needed.
Mucolipidosis type IV is an ultra-rare disease with fewer than about 300 patients reported worldwide. Systematic epidemiological data on prevalence and incidence are lacking, but the incidence in the Ashkenazi Jewish population is estimated at about 1 per 40,000 births. Patients from this population account for the majority of cases reported worldwide, but sporadic cases have also been reported in non-Jewish populations, including Arab, European, and Asian populations.
The carrier rate of about 1/100 among Ashkenazi Jews suggests that mucolipidosis type IV is a biologically meaningful population genetic problem in this population, and it is included in the "Enpanek (Expanded carrier screening for Ashkenazi Jewish genetic diseases)" test panel performed in this population. There is no sex difference (autosomal recessive). In Korea, reported cases are very rare, and it is designated as an ultra-rare disease (Special Copayment Reduction V117).
In non-Jewish populations, MCOLN1 gene abnormalities have been reported individually in various ethnic and population groups, so it is understood to occur worldwide without a particular ethnic bias. Owing to lack of diagnostic awareness and rarity, a considerable number of patients worldwide are presumed to be undiagnosed.
In normal cells, TRPML1 is activated at acidic lysosomal pH by a luminal-facing loop of the lysosomal membrane and releases Ca²⁺ from the lysosomal lumen into the cytoplasm. This local Ca²⁺ release promotes SNARE complex assembly and the membrane fusion process by which the lysosomal membrane and the late endosome membrane fuse. TRPML1-mediated Ca²⁺ release is also essential for lysosomal exocytosis, in which lysosomes fuse directly with the plasma membrane and expel their contents outside the cell.
In TRPML1 deficiency, this Ca²⁺ release is blocked and the following cascade of abnormalities occurs. First, late endosome → lysosome trafficking is blocked, so endosomal contents—phospholipids, gangliosides, membrane proteins, etc.—accumulate secondarily in endosomes and lysosomes. Second, autophagosomes cannot fuse with lysosomes, blocking autophagic flux and causing accumulation of abnormal organelles such as damaged mitochondria. Third, blockade of lysosomal exocytosis also closes off the pathway for extracellular expulsion of accumulated substances.
TRPML1 is also involved in a pathway that promotes nuclear translocation of transcription factor EB (TFEB). TFEB is a master transcriptional regulator of genes related to lysosome biogenesis and autophagy, and in TRPML1 deficiency, nuclear translocation of TFEB is reduced, so lysosome biogenesis itself also decreases. mTORC1 kinase phosphorylates TFEB and retains it in the cytoplasm, and TRPML1 in turn affects the regulation of mTORC1 activity. Disruption of this mTORC1-TFEB-TRPML1 reciprocal regulatory circuit is recognized as an important aspect of the pathophysiology of ML-IV.
In the brain, axonal damage (axonal spheroid formation) due to blocked autophagic flux is observed in neuronal axons and dendrites. In the retina, lysosomal trafficking defects in the retinal pigment epithelium (RPE) prevent phagocytosis and reprocessing of photoreceptor outer segment discs, causing RPE cell dysfunction and photoreceptor degeneration. In the cornea, accumulation of material within lysosomes of corneal stromal cells (keratocytes) reduces corneal transparency.
The clinical symptoms of mucolipidosis type IV are broadly divided into neurological, ophthalmologic, and gastrointestinal symptoms. An important clinical feature is that, unlike other mucolipidoses (ML types I–III), there is no visceromegaly, no coarse facial dysmorphism, and no urinary excretion of oligosaccharides or mucopolysaccharides.
Ophthalmologic symptoms: The most common and earliest clinical finding is corneal clouding. Parents or pediatricians often notice diffuse stromal clouding of the cornea within several months to 1 year after birth. The clouding progresses slowly over time. Along with this, retinal degeneration develops, and fundus examination shows retinal pigmentary degeneration and optic pallor. Visual impairment is due to both corneal clouding and retinal degeneration and worsens as the disease progresses.
Neurodevelopmental and neurological symptoms: Psychomotor developmental delay is recognized within several months after birth. Motor development is markedly delayed, and most patients never achieve independent walking or achieve it very late. Language development is also severely delayed. Severe cognitive impairment is present. Hypotonia appears initially, later gradually progressing to spastic quadriplegia. Seizures are relatively rare. An important feature is that the neurological symptoms tend not to show dramatic rapid regression as in other neurological lysosomal storage diseases, but rather to remain in a plateau state. That is, the developmental delay is fixed and plateaus at an early level rather than showing severe progressive regression.
Gastrointestinal and endocrine symptoms: In almost all patients with mucolipidosis type IV, serum gastrin is markedly elevated. This is presumed to be because lysosomal trafficking defects in gastric parietal cells block gastric acid secretion, increasing gastrin secretion through a feedback mechanism. Clinically evident gastrointestinal symptoms are often absent, but some patients have recurrent vomiting and feeding difficulties. Achlorhydria (lack of gastric acid) is also present in some cases.
Ophthalmologic signs: Slit-lamp examination shows diffuse stromal clouding throughout the corneal stroma. The clouding is usually bilateral and shows a punctate or diffuse pattern. The corneal clouding itself causes decreased vision. Fundus examination shows retinal pigmentary degeneration (bone spicule pigmentation), optic pallor, and attenuated retinal vessels. Electroretinography (ERG) shows reduced photoreceptor responses.
Neurological signs: Spastic quadriplegia progressing after initial hypotonia, hyperreflexia, and a positive Babinski sign are observed. Signs of cerebellar ataxia are reported in some. Seizures are rare. Cognitive assessment shows moderate to severe intellectual disability.
Brain MRI findings: Hypoplastic/dysgenetic corpus callosum is characteristically observed in ML-IV. Hypoplasia of the posterior corpus callosum (splenium) is especially prominent. White matter signal abnormalities (T2 hyperintensity) and structural abnormalities of the basal ganglia (especially the caudate nucleus and putamen) are also seen. Brain atrophy is mild in the early stage of the disease. This MRI pattern is a very strong clue to the diagnosis of ML-IV.
Skin and conjunctival biopsy: Electron microscopy shows lysosomal vacuolization and various contents (lamellar inclusions, membranous bodies, granular inclusions) in the cytoplasm of skin fibroblasts, conjunctival cells, and lymphocytes. This is used to support the diagnosis.
Serum gastrin: In almost all ML-IV patients, serum gastrin is markedly elevated to several to dozens of times the upper limit of normal. This finding is very useful as a rapid, noninvasive screening test when clinically suspected. However, other causes such as Helicobacter pylori infection and atrophic gastritis must be excluded.
Newborn screening of the general population for mucolipidosis type IV has not currently been established. A factor making newborn screening difficult is that, because lysosomal hydrolase activity is normal, it cannot be detected by existing DBS enzyme-based screening methods.
Screening of the Ashkenazi Jewish population: In this population, DNA-based carrier screening for the two MCOLN1 founder variants (IVS3-2A→G, del6.4kb) before a planned pregnancy or in early pregnancy is included as a standard recommendation. Expanded carrier screening panels for Jewish genetic diseases (e.g., the Dor Yeshorim program) include these two variants. If both variants are negative, the residual risk in this population is very low.
Clinical screening clues: The combination of infantile corneal clouding and psychomotor developmental delay is a strong clinical clue that should immediately raise suspicion of ML-IV. Serum gastrin measurement is noninvasive, inexpensive, and highly sensitive, and is a screening test that should be performed immediately when clinically suspected. If gastrin is markedly elevated, proceed with confirmation by MCOLN1 gene analysis.
Imaging screening: If the characteristic pattern of hypoplastic corpus callosum and basal ganglia abnormalities is seen on brain MRI, ML-IV should be strongly suspected and genetic testing performed. This MRI pattern is an important clue distinguishing it from other lysosomal diseases.
MCOLN1 gene analysis is key to confirming mucolipidosis type IV, and clinical, radiological, and biochemical findings complement the diagnosis.
Molecular genetic testing: Pathogenic variants in both alleles are identified by Sanger sequencing or NGS-based analysis of the MCOLN1 gene. In Ashkenazi Jewish patients, testing targeting the two founder variants (IVS3-2A→G, del6.4kb) is fast and efficient. Large deletions are detected by MLPA.
Serum gastrin measurement: Markedly elevated in almost all ML-IV patients, so sensitivity is very high. It is not a confirmatory test but is used as a basis for rapid clinical suspicion. It is a useful biochemical marker for early detection of other undiagnosed ML-IV patients.
Cell and tissue studies: Electron microscopy of skin fibroblasts or conjunctival biopsy shows characteristic lysosomal vacuoles and membranous inclusions (lamellar bodies, granular inclusions). Lymphocyte vacuoles may be seen on blood smear. These findings play a supportive rather than confirmatory role in diagnosis.
Imaging studies: On brain MRI, hypoplasia of the corpus callosum (especially the posterior corpus callosum), white matter signal abnormalities, and structural abnormalities of the basal ganglia are characteristic. ERG (electroretinography) shows reduced photoreceptor responses. Visual evoked potentials (VEP) show reduced amplitude and delay.
Differential diagnosis: Differentiation is needed from other metabolic diseases with corneal clouding (Fabry disease—angiokeratoma, HRT present; cystinosis—cystine crystals; Wilson disease—Kayser-Fleischer ring), other mucolipidoses (ML I–III—increased urinary oligosaccharides, enzyme abnormalities), and lysosomal membrane protein deficiency diseases (NPC, LAMP2 deficiency, etc.). Normal urinary oligosaccharides and lysosomal enzyme activities are the key to differentiating it from other MLS/MPS.
As of 2026, there is no established curative treatment for mucolipidosis type IV. Treatment focuses on symptom management and improving quality of life, and the following research approaches are under way.
Ophthalmologic treatment: When decreased vision due to corneal clouding is severe, corneal transplantation (penetrating keratoplasty) is performed. Vision may improve temporarily after corneal transplantation, but the grafted cornea may also become clouded again over time. There is currently no available treatment for retinal pigmentary degeneration. Function is supported by prescribing low-vision aids and visual rehabilitation.
Neurodevelopmental and rehabilitation therapy: Physical therapy, occupational therapy, and speech therapy support improvement in developmental level and maintenance of function. For spasticity, muscle relaxants (baclofen, diazepam), Botox injections, and physical stretching exercises are applied. Anticonvulsants are given if seizures occur.
mTORC1 inhibition therapy (preclinical): In the TRPML1-mTORC1-TFEB reciprocal regulatory circuit, inhibiting mTORC1 increases TFEB nuclear translocation, increasing lysosome biogenesis and autophagy. Rapamycin showed improvement in lysosomal trafficking in MCOLN1-deficient mouse models, but clinical application is still at the research stage.
Small molecules enhancing TRPML1 function (preclinical): Synthetic TRPML1 agonists such as SF-22 and ML-SA1 have been reported to activate the TRPML1 channel at the cellular level and improve lysosomal trafficking. In variant combinations with residual function, pharmacological chaperone or agonist approaches are being studied as potential therapeutic strategies.
Gene therapy: AAV-based gene therapy for MCOLN1 gene delivery is being explored in cell and mouse models. Local administration routes to the brain and retina are under study.
Mucolipidosis type IV shows a relatively slow course compared with other neurological lysosomal storage diseases. Most patients survive into adulthood, but global developmental delay and visual impairment remain fixed or progress slowly.
Developmentally, most patients have moderate to severe intellectual disability, and independent daily functioning is very limited. About 15% of patients are reported to have a mild clinical course and be able to walk and communicate at a basic level. Dramatic regression of neurological function itself is less common than in other neurological lysosomal diseases, and there is a characteristic "plateau" at the early developmental level. However, in some patients neurological function may gradually deteriorate after adolescence.
Visual function gradually declines over time due to both corneal clouding and retinal degeneration. Vision may improve temporarily with corneal transplantation, but retinal degeneration progresses. Some patients become blind after middle age. Gastrointestinal symptoms are generally mild and do not greatly affect prognosis.
Early rehabilitation intervention, use of visual aids, and appropriate educational support are important for maintaining function and improving quality of life. Improvement in prognosis is expected if curative treatments are developed, but this is not currently possible.
Prevention of mucolipidosis type IV centers on secondary prevention through carrier screening, genetic counseling, prenatal diagnosis, and preimplantation genetic testing.
Carrier screening in the Ashkenazi Jewish population: DNA testing for the two founder variants (IVS3-2A→G, del6.4kb) is performed before a planned pregnancy. If both parents are carriers of the same variant, there is a 25% risk of an affected child with each pregnancy.
Genetic counseling: Carrier couples are given a thorough explanation of recurrence risk, prenatal diagnostic methods, and the PGT-M option. Families who already have an affected child are advised about sibling recurrence risk and carrier testing of the extended family.
Prenatal diagnosis: Based on the MCOLN1 variant identified in the family, fetal DNA is analyzed by CVS (11–14 weeks) or amniocentesis (15–20 weeks) to determine whether the fetus is affected.
Preimplantation genetic testing (PGT-M): During in vitro fertilization, after embryo biopsy, MCOLN1 variant analysis is used to exclude affected embryos, and only normal or carrier embryos are implanted. This is possible when the variants of both parents have been identified.